KCAS Acquires FlowMetric
BroadOak Partners advised KCAS, a Vitruvian Partners portfolio company, on the acquisition of FlowMetric, LLC. FlowMetric is a leading provider of flow cytometry and cellular assay R&D services to biotech, pharmaceutical and cell and gene therapy industries. The full press release is below. KCAS Bioanalytical and Biomarker Services, a Vitruvian Partners portfolio Company, announces acquisition […]
MyChem Sells To Maravai LifeSciences
BroadOak Partners advises MyChem, LLC on the sale of the company to Maravai LIfeSciences (NASDAQ: MRVI). MyChem is a leading provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics, and research markets. The full press release is below. MyChem’s nucleotide synthesis methods are highly complementary to Maravai’s TriLink mRNA technologies Increases capabilities […]
JMI Announces Sale to Element Materials Technology
BroadOak Capital Partners advised JMI Laboratories (“JMI”) on the sale of the company to Element Materials Technology (“Element”). JMI is a leading provider of antimicrobial drug development, molecular testing, clinical trial support, and surveillance services to biotech and pharmaceutical companies. The full press release is below. Element strengthens pharmaceutical and biotech capability with JMI Laboratories […]
BroadOak Provides $8M Loan to Interpace Biosciences
BroadOak Capital Partners provided a senior term loan to refinance debt held by Interpace’s private equity stockholders, Ampersand Capital and 1315 Capital. Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. The full press release is […]
Nanosyn Sells to Element Materials Technology
BroadOak Partners advises Nanosyn on the sale of the company to Element Materials Technology (“Element”). Nanoysn is a full-service drug discovery CDMO that provides chemistry, biology, API, and formulation services to pharmaceutical companies. The full press release is below. Element further bolsters its pharmaceuticals offering with Nanosyn acquisition London, UK – October 11, 2021 – […]
BroadOak Leads Acquisition of Particle Dynamics
An investor group led by BroadOak Capital Partners acquired Particle Dynamics from Edgewater Capital Partners. Particle Dynamics is a global leader in particle processing, delivery technologies, and finished dose manufacturing for the pharmaceutical, over-the-counter, and nutraceutical markets. The full press release is below. Particle Dynamics Announces Sale to New Ownership Group Led by BroadOak Capital […]
PBS Biotech Raises $10M in Growth Capital
Single-use bioreactor manufacturer, PBS Biotech, recently closed a private $10M funding round with BroadOak Capital Partners. The financing will enable the company to expand and industrialize its portfolio of single-use bioreactor systems and contract process development services. The full press release is below. PBS Biotech Raises $10M to Provide Scale-Up Manufacturing Solutions for Cell Therapies […]
Vigene Biosciences Acquired by Charles River Laboratories
BroadOak portfolio company Vigene Biosciences was acquired by Charles River Laboratories. Vigene Biosciences is a leading CDMO providing viral vector manufacturing services for the cell and gene therapy market. The full press release is below. Charles River Laboratories Completes Acquisition of Vigene Biosciences WILMINGTON, Mass.–(BUSINESS WIRE)–Jun. 29, 2021– Charles River Laboratories International, Inc. (NYSE: CRL) […]
KCAS Sells To Vitruvian
BroadOak Capital Partners advised KCAS Bioanalytical and Biomarker Services (“KCAS”) on the sale of the company to Vitruvian. KCAS is a leading contract research organization providing comprehensive GLP-compliant bioanalytical and biomarker development testing services for the biotech, pharmaceutical, and animal health industries. The full press release is below. Vitruvian Partners announces strategic growth investment in […]
Kromatid Receives $2M Investment From BroadOak Capital Partners
BroadOak Capital Partners invested growth capital in KromaTiD. KromaTiD sells structural genomic products and tech-enabled services to optimize gene editing for research and clinical purposes. The funding will help accelerate the commercialization of its recently launched direction genomic hybridization In-Site and SCREEN products for gene editing and gene therapy applications. The full press release is […]